Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 12,74 € (+52,39 %). La mediana es de 12,74 € (+52,39 %).
| Comprar |
7 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
908 Devices focuses on handheld detection devices and strengthens financial profile
908 Devices announces a strategic focus on handheld chemical detectors intended to drive faster growth, improved margins and reduced cash burn. Revenue rose 23% in Q2 2026 to $16.1m, adjusted EBITDA loss for the quarter fell to below $2m, and the company reports $101.5m in cash with no debt. The 2026 revenue guidance was raised to $68–70m; recurring revenue is around 30% and is expected to grow further through the acquisition of NIRLab. 908 Devices highlights large market opportunities (opioid crisis, defense, border security) and an installed base of more than 4,100 devices with 700 customers in over 70 countries. » Más en de.investing.com
908 Devices reports 23% revenue growth in Q2 2026 and halves adjusted EBITDA loss
908 Devices posted Q2 2026 revenue of $16.1 million, up 23% year‑over‑year, driven by FTIR product shipments and U.S. state and local demand. Adjusted EBITDA loss narrowed to about $1.9 million, a roughly 50% improvement, while adjusted gross margin rose to ~57%. The company closed the NIRLAB acquisition, sold 35+ NIRLAB units with multiyear subscriptions, and secured a $6 million ProtectIR order for APAC. Cash and equivalents were $101.5 million with no debt, and full‑year revenue guidance was raised to $68–70 million, excluding potential AVCAD program upside. » Más en finance.yahoo.com
908 Devices focuses on handheld detection devices and reports solid financials
At the Growth Conference, 908 Devices presented a strategic shift away from medical technology toward handheld mass spectrometers for defense, law enforcement and public safety. The company has more than USD 100 million in liquidity and an adjusted EBITDA in the mid-single-digit millions, providing several years of financial runway. The product range spans the low-cost NIRLab to the flagship MX908; a new, more compact MX908 generation is planned for late 2026. Government grant programs and military projects such as AVCAD, together with growing international demand, are cited as the main growth drivers. » Más en de.investing.com
908 Devices accelerates transformation despite missed earnings expectation
908 Devices reported Q1 2026 revenue of $13.4 million (+14% y/y) and improved adjusted gross margin (57%) as well as adjusted EBITDA (-$2.5 million). EPS of -$0.32 missed estimates mainly due to a $6.4 million contingent consideration from acquisitions, while GAAP losses persist. The balance sheet is debt-free with $112 million in cash; the company is growing its installed base and recurring revenues, and the new VipIR device is expected to drive growth in 2026. For 2026, 908 Devices forecasts revenue of $67–70 million and an improvement in adjusted EBITDA to the mid-single-digit millions, but remains dependent on integration costs and the conversion to sustainable GAAP profitability. » Más en de.investing.com
908 Devices appoints Kola Otitoju as chief business & strategy officer
908 Devices has appointed Kola Otitoju to the newly created role of chief business & strategy officer; he will drive product and corporate strategy, business development, M&A and partnerships. Otitoju brings more than 25 years of experience in strategy, business development and P&L management, most recently serving as senior vice president at Repligen Corporation. The board granted him 110,193 RSUs and options on 146,789 common shares with an exercise price of $7.26; both awards vest over three years. The appointment comes after the stock rose 52% over the past year, though the company still reports a loss of $0.93 per share; the balance sheet is viewed as well capitalized/liquid. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 16,73 M | 40,19 % |
| Beneficio bruto | 8,84 M | 50,43 % |
| Beneficio neto | -4,04 M | 68,18 % |
| EBITDA | -4,09 M | 65,22 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 368,45 M € |
Número de acciones | 41,58 M |
Máximo/mínimo de 52 semanas | 12,14 € - 4,57 € |
| Dividendos | No |
Beta | 0,63 |
Ratio P/E | -15,46 |
Ratio PEG | 0,01 |
Ratio P/B | 2,67 |
Ratio P/S | 6,16 |
Perfil de la empresa
908 Devices Inc., una empresa tecnológica en fase de comercialización, ofrece diversos dispositivos de espectrometría de masas (Mass Spec) de mesa y portátiles diseñados a medida para analizar materiales desconocidos e invisibles en la investigación en ciencias de la vida, el bioprocesamiento, la biotecnología industrial, la criminalística y mercados afines. Los productos de la empresa incluyen MX908, un dispositivo de espectrometría de masas portátil y alimentado por batería, diseñado para el análisis rápido de materiales gaseosos, líquidos y sólidos de identidad desconocida; Rebel, un analizador compacto de sobremesa que proporciona información en tiempo real sobre el entorno extracelular en los bioprocesos; y ZipChip, una plataforma de separación de alta resolución lista para usar (plug-and-play) que optimiza el análisis de muestras por espectrometría de masas. Opera en las Américas, Europa, Oriente Medio, África y Asia-Pacífico. La empresa se constituyó en 2012 y tiene su sede en Boston, Massachusetts.
| Nombre | 908 DEVICES INC. DL-,001 |
| CEO | Kevin J. Knopp |
| Sede | Burlington,
ma Japón |
| Sitio web | |
| Sector | Servicios públicos |
| Industria | Equipos y servicios energéticos |
| Salida a bolsa | 18/03/2010 |
| Empleados | 172 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | MASS |